MCID: SKN022
MIFTS: 41

Skin Squamous Cell Carcinoma malady

Categories: Cancer diseases, Skin diseases

Aliases & Classifications for Skin Squamous Cell Carcinoma

Aliases & Descriptions for Skin Squamous Cell Carcinoma:

Name: Skin Squamous Cell Carcinoma 12 14
Squamous Cell Carcinoma of Skin 12 69
Epidermoid Skin Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3151
NCIt 47 C4819
SNOMED-CT 64 254651007
UMLS 69 C0553723

Summaries for Skin Squamous Cell Carcinoma

Disease Ontology : 12 A skin carcinoma that has material basis in squamous cells.

MalaCards based summary : Skin Squamous Cell Carcinoma, also known as squamous cell carcinoma of skin, is related to palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal and pseudovascular skin squamous cell carcinoma. An important gene associated with Skin Squamous Cell Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Toll-like Receptor Signaling Pathway. The drugs Cetuximab and Imiquimod have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and monocytes, and related phenotypes are endocrine/exocrine gland and hematopoietic system

Related Diseases for Skin Squamous Cell Carcinoma

Graphical network of the top 20 diseases related to Skin Squamous Cell Carcinoma:



Diseases related to Skin Squamous Cell Carcinoma

Symptoms & Phenotypes for Skin Squamous Cell Carcinoma

MGI Mouse Phenotypes related to Skin Squamous Cell Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.7 BIRC5 IL10 KLF4 LGR5 MGMT STAT1
2 hematopoietic system MP:0005397 9.56 TP53 AKR1C3 BIRC5 CD151 IL10 KLF4
3 neoplasm MP:0002006 9.23 CD151 EIF4E IL10 KLF4 LGR5 MGMT

Drugs & Therapeutics for Skin Squamous Cell Carcinoma

Drugs for Skin Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 231)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
2
Imiquimod Approved, Investigational Phase 4,Phase 2,Phase 3 99011-02-6 57469
3
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
4
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
5
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
6
Cyclosporine Approved, Investigational, Vet_approved Phase 4 79217-60-0, 59865-13-3 5284373 6435893
7
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
9
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
10
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 445643 439492
11
Ethanol Approved Phase 4 64-17-5 702
12
Acitretin Approved Phase 4,Phase 2 55079-83-9 6437841 5284513
13
Petrolatum Approved Phase 4 8009-03-8
14 Titanium dioxide Approved Phase 4 13463-67-7
15
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
16
Technetium tc 99m sulfur colloid Approved Phase 4
17
Azathioprine Approved Phase 4 446-86-6 2265
18
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
19
Mycophenolic acid Approved Phase 4 24280-93-1 446541
20
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
21 Adjuvants, Immunologic Phase 4,Phase 2,Phase 3,Phase 1
22 Interferon Inducers Phase 4,Phase 2,Phase 3
23 interferons Phase 4,Phase 2,Phase 3,Phase 1
24 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
25 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
26 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
27 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Tin Fluorides Phase 4
30 triamcinolone acetonide Phase 4,Phase 2
31 Triamcinolone diacetate Phase 4,Phase 2
32 Triamcinolone hexacetonide Phase 4,Phase 2
33 Analgesics Phase 4,Phase 2
34 Analgesics, Non-Narcotic Phase 4,Phase 2
35 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 1
36 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
37 Antirheumatic Agents Phase 4,Phase 2
38 Cyclooxygenase Inhibitors Phase 4,Phase 2
39 Peripheral Nervous System Agents Phase 4,Phase 2
40 Retinol palmitate Phase 4
41 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
43 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Calcineurin Inhibitors Phase 4,Phase 3
45 Keratolytic Agents Phase 4,Phase 3,Phase 2
46 Anti-Allergic Agents Phase 4
47 mometasone furoate Phase 4 83919-23-7
48 Radiopharmaceuticals Phase 4,Phase 1,Phase 2
49 Anticoagulants Phase 4
50 Blood Substitutes Phase 4

Interventional clinical trials:

(show top 50) (show all 247)
id Name Status NCT ID Phase
1 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) Unknown status NCT01553032 Phase 4
2 Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses Unknown status NCT01229319 Phase 4
3 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4
4 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2) Completed NCT01453179 Phase 4
5 Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients Completed NCT00129961 Phase 4
6 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Recruiting NCT02495064 Phase 4
7 Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5% Active, not recruiting NCT01926496 Phase 4
8 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Active, not recruiting NCT02287675 Phase 4
9 Acitretin Plasma Levels Under Hemodialysis Suspended NCT00488384 Phase 4
10 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4
11 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4
12 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
13 Topical Imiquimod for Bowen's Disease of the Head and Neck Unknown status NCT00384124 Phase 2, Phase 3
14 Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck Completed NCT00193895 Phase 3
15 Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer Completed NCT00005884 Phase 3
16 TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients Completed NCT00133887 Phase 3
17 Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer Completed NCT00006481 Phase 3
18 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
19 PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin Cancer Completed NCT00472459 Phase 3
20 Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT Completed NCT01931150 Phase 3
21 Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer Completed NCT00007631 Phase 3
22 Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses Completed NCT00175643 Phase 3
23 A Comparative Study of the Healing of Chronic Ulcers of Recessive Epidermolysis Bullosa : Dressing vs Amniotic Membrane Recruiting NCT02286427 Phase 3
24 E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck Recruiting NCT02630264 Phase 3
25 Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Recruiting NCT00956007 Phase 3
26 Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions Recruiting NCT02059499 Phase 3
27 Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Active, not recruiting NCT01362140 Phase 3
28 A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp Not yet recruiting NCT03115476 Phase 3
29 Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery Not yet recruiting NCT02997553 Phase 3
30 Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients Terminated NCT01532453 Phase 3
31 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3
32 Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC) Unknown status NCT01129154 Phase 2
33 Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer Unknown status NCT00423397 Phase 1, Phase 2
34 Low Fat Diet to Prevent Disease Progression in Patients With Skin Cancer Unknown status NCT00003097 Phase 2
35 Treatment Selection According to Skin Reaction to Cetuximab Unknown status NCT01472653 Phase 2
36 Phase II AK Study in Organ Transplant Patients Unknown status NCT00829192 Phase 2
37 A Study of Intensity-modulated Radiotherapy in Patients With Squamous Cell Carcinoma of Unknown Primary (SCCUP) of the Head and Neck Unknown status NCT02112344 Phase 1, Phase 2
38 Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer Unknown status NCT01158248 Phase 2
39 Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer Completed NCT00126555 Phase 2
40 Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR Completed NCT00240682 Phase 2
41 Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia Completed NCT00563290 Phase 2
42 Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ Completed NCT00329121 Phase 2
43 An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS) Completed NCT00652080 Phase 1, Phase 2
44 ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin Completed NCT00054691 Phase 2
45 A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma Completed NCT00369512 Phase 2
46 Clinical Study Assessment of SR-T100 Topical Gel Against Actinic Keratosis Completed NCT02085395 Phase 2
47 Photodynamic Therapy in Treating Patients With Skin Cancer Completed NCT00002963 Phase 2
48 Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck Completed NCT00519077 Phase 2
49 Photodynamic Therapy in Treating Patients With Skin Cancer Completed NCT00002975 Phase 2
50 Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis Completed NCT00021294 Phase 2

Search NIH Clinical Center for Skin Squamous Cell Carcinoma

Genetic Tests for Skin Squamous Cell Carcinoma

Anatomical Context for Skin Squamous Cell Carcinoma

MalaCards organs/tissues related to Skin Squamous Cell Carcinoma:

39
Skin, Lung, Monocytes, Breast

Publications for Skin Squamous Cell Carcinoma

Articles related to Skin Squamous Cell Carcinoma:

(show top 50) (show all 60)
id Title Authors Year
1
A case report of Muir-Torre syndrome in a woman with breast cancer and MSI-Low skin squamous cell carcinoma. ( 28507641 )
2017
2
Erratum: Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. ( 26845409 )
2016
3
Antimicrobial peptide LL-37 promotes the proliferation and invasion of skin squamous cell carcinoma by upregulating DNA-binding protein A. ( 27588122 )
2016
4
Predicted cases of U.K. skin squamous cell carcinoma and basal cell carcinoma in 2020 and 2025: horizon planning for National Health Service dermatology and dermatopathology. ( 27714753 )
2016
5
DC vaccine generated by ALA-PDT-induced immunogenic apoptotic cells for skin squamous cell carcinoma. ( 27471605 )
2016
6
The genetic evolution of skin squamous cell carcinoma: tumor suppressor identity matters. ( 27193637 )
2016
7
Inhibition of skin squamous cell carcinoma proliferation and promote apoptosis by dual silencing of NET-1 and survivin. ( 26080853 )
2015
8
Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. ( 26168291 )
2015
9
Exposure to moxifloxacin and cytomegalovirus replication is associated with skin squamous cell carcinoma development in lung transplant recipients. ( 26403508 )
2015
10
Autophagy in human skin squamous cell carcinoma: Inhibition by 3-MA enhances the effect of 5-FU-induced chemotherapy sensitivity. ( 26398820 )
2015
11
Ginsenoside rh2 inhibits cancer stem-like cells in skin squamous cell carcinoma. ( 25966742 )
2015
12
Improvement of DC vaccine with ALA-PDT induced immunogenic apoptotic cells for skin squamous cell carcinoma. ( 25915530 )
2015
13
TIPE2 regulates tumor-associated macrophages in skin squamous cell carcinoma. ( 26577853 )
2015
14
Efficacy of elective nodal irradiation in skin squamous cell carcinoma of the face, ears, and scalp. ( 26391010 )
2015
15
Inhibitory effect of berberine on human skin squamous cell carcinoma A431 cells. ( 26400287 )
2015
16
Clinical significance of STAT3 and MAPK phosphorylation, and the protein expression of cyclin D1 in skin squamous cell carcinoma tissues. ( 26497194 )
2015
17
Inhibitory effect of curcumin on invasion of skin squamous cell carcinoma a431 cells. ( 25854367 )
2015
18
Skin squamous cell carcinoma presenting as cellulitis. ( 25635168 )
2015
19
Clinical significance of methylation of E-cadherin and p14ARF gene promoters in skin squamous cell carcinoma tissues. ( 25126184 )
2014
20
Aldo-keto reductase 1C3 is overexpressed in skin squamous cell carcinoma (SCC) and affects SCC growth via prostaglandin metabolism. ( 24917395 )
2014
21
Advanced skin squamous cell carcinoma: role of radiotherapy. ( 24563891 )
2014
22
Lgr5-positive cells are cancer stem cells in skin squamous cell carcinoma. ( 25135431 )
2014
23
Sox2, a marker for stem-like tumor cells in skin squamous cell carcinoma and hedgehog subgroup medulloblastoma. ( 25061226 )
2014
24
Lung transplant recipients receiving voriconazole and skin squamous cell carcinoma risk in Australia. ( 25358582 )
2014
25
Immunohistochemical analysis of O(6)-methylguanine-DNA methyltransferase in human melanoma in comparison with skin squamous cell carcinoma. ( 23460078 )
2013
26
Tetraspanin CD151 plays a key role in skin squamous cell carcinoma. ( 22824799 )
2013
27
The inhibition of resveratrol to human skin squamous cell carcinoma A431 xenografts in nude mice. ( 23428654 )
2013
28
HPV type 16-induced skin squamous cell carcinoma located on the groin of immunocompetent patients. ( 24116660 )
2013
29
Expression and function of NET-1 in human skin squamous cell carcinoma. ( 24196235 )
2013
30
Pronounced allelic imbalance at D9S162 in skin squamous cell carcinoma of organ transplant recipients. ( 22508773 )
2012
31
Skin squamous cell carcinoma propagating cells increase with tumour progression and invasiveness. ( 23188079 )
2012
32
Upregulation of TCTP expression in human skin squamous cell carcinoma increases tumor cell viability through anti-apoptotic action of the protein. ( 22969908 )
2012
33
Curcumin inhibits skin squamous cell carcinoma tumor growth in vivo. ( 21493306 )
2011
34
The incidence of skin squamous cell carcinoma in Osijek-Baranja County--an epidemiological study. ( 22220409 )
2011
35
C/EBPI+ expression is downregulated in human nonmelanoma skin cancers and inactivation of C/EBPI+ confers susceptibility to UVB-induced skin squamous cell carcinomas. ( 21346772 )
2011
36
Involvement of VILIP-1 (visinin-like protein) and opposite roles of cyclic AMP and GMP signaling in in vitro cell migration of murine skin squamous cell carcinoma. ( 21480386 )
2011
37
Association of the DSS1 c.143G>A polymorphism with skin squamous cell carcinoma. ( 20220765 )
2010
38
[Expression, clinical and pathological significance of KIAA1173 gene in skin squamous cell carcinoma]. ( 20646595 )
2010
39
Immune phenotype of peripheral blood cells and skin squamous cell carcinoma in organ transplant recipients. ( 20441422 )
2010
40
Etretinate enhances the susceptibility of human skin squamous cell carcinoma cells to 5-aminolaevulic acid-based photodynamic therapy. ( 19077103 )
2009
41
Desipramine inhibits the growth of a mouse skin squamous cell carcinoma cell line and affects glucocorticoid receptor-mediated transcription. ( 19575421 )
2009
42
The preventive effect of calcitriol on skin squamous cell carcinoma may be due to its effect on prostaglandin E2 metabolism and biologic activity. ( 20021988 )
2009
43
[Functions of NET-1 gene in skin squamous cell carcinoma cell line (A431): a siRNA study]. ( 20078975 )
2009
44
Downregulation of tazarotene induced gene-2 (TIG2) in skin squamous cell carcinoma. ( 18955196 )
2008
45
Nuclear KrA1ppel-like factor 4 expression is associated with human skin squamous cell carcinoma progression and metastasis. ( 18376139 )
2008
46
Thioredoxin upregulation by 5-aminolaevulinic acid-based photodynamic therapy in human skin squamous cell carcinoma cell line. ( 18477133 )
2008
47
Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. ( 17513803 )
2007
48
Significance of eIF4E expression in skin squamous cell carcinoma. ( 17689990 )
2007
49
Interleukin-10 promoter polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation. ( 12535204 )
2003
50
Dominant negative signal transducer and activator of transcription 2 (STAT2) protein: stable expression blocks interferon alpha action in skin squamous cell carcinoma cells. ( 12748307 )
2003

Variations for Skin Squamous Cell Carcinoma

ClinVar genetic disease variations for Skin Squamous Cell Carcinoma:

6 (show all 21)
id Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
2 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
3 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
4 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
5 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
6 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
7 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
8 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
9 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
10 BRAF NM_004333.4(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
11 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
12 BRAF NM_004333.4(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
13 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
14 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
15 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
16 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
17 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587782289 GRCh37 Chromosome 17, 7577575: 7577575
18 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh38 Chromosome 11, 534285: 534285
19 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
20 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh37 Chromosome 17, 7577082: 7577082
21 TP53 NM_000546.5(TP53): c.833C> T (p.Pro278Leu) single nucleotide variant Pathogenic/Likely pathogenic rs876659802 GRCh37 Chromosome 17, 7577105: 7577105

Cosmic variations for Skin Squamous Cell Carcinoma:

9 (show top 50) (show all 3299)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM4990873 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.878C>T p.S293L 13
2 COSM703213 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.1817C>T p.P606L 13
3 COSM4990875 ZNF668 skin,NS,carcinoma,squamous cell carcinoma c.247C>T p.P83S 13
4 COSM4990310 ZMYM2 skin,NS,carcinoma,squamous cell carcinoma c.946C>T p.Q316* 13
5 COSM4990309 ZMYM2 skin,NS,carcinoma,squamous cell carcinoma c.946C>T p.Q316* 13
6 COSM4991869 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.282C>G p.A94A 13
7 COSM4991861 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.876G>C p.P292P 13
8 COSM4991867 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.314T>G p.V105G 13
9 COSM4991863 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.569A>C p.K190T 13
10 COSM4991865 ZIC4 skin,NS,carcinoma,squamous cell carcinoma c.522C>T p.F174F 13
11 COSM4990301 ZIC2 skin,NS,carcinoma,squamous cell carcinoma c.915G>A p.E305E 13
12 COSM3184673 ZFP36L2 skin,NS,carcinoma,squamous cell carcinoma c.569C>T p.P190L 13
13 COSM3184669 ZFP36L2 skin,NS,carcinoma,squamous cell carcinoma c.596C>T p.T199I 13
14 COSM4991542 ZBED4 skin,NS,carcinoma,squamous cell carcinoma c.328C>T p.R110W 13
15 COSM4993525 ZBED1 skin,NS,carcinoma,squamous cell carcinoma c.601T>G p.W201G 13
16 COSM4991780 XPO1 skin,NS,carcinoma,squamous cell carcinoma c.2285G>A p.W762* 13
17 COSM4829120 XPC skin,NS,carcinoma,squamous cell carcinoma c.1439C>T p.S480F 13
18 COSM4991848 XPC skin,NS,carcinoma,squamous cell carcinoma c.2255C>T p.P752L 13
19 COSM4991847 XPC skin,NS,carcinoma,squamous cell carcinoma c.2445G>A p.E815E 13
20 COSM4991849 XPC skin,NS,carcinoma,squamous cell carcinoma c.2254C>T p.P752S 13
21 COSM4991846 XPC skin,NS,carcinoma,squamous cell carcinoma c.2446G>A p.E816K 13
22 COSM4990181 WT1 skin,NS,carcinoma,squamous cell carcinoma c.726C>A p.N242K 13
23 COSM4990704 VTI1B skin,NS,carcinoma,squamous cell carcinoma c.274C>T p.H92Y 13
24 COSM4991824 UMPS skin,NS,carcinoma,squamous cell carcinoma c.332G>A p.G111E 13
25 COSM4991826 UMPS skin,NS,carcinoma,squamous cell carcinoma c.843G>A p.K281K 13
26 COSM4991823 UMPS skin,NS,carcinoma,squamous cell carcinoma c.331G>A p.G111R 13
27 COSM4990645 TTLL7 skin,NS,carcinoma,squamous cell carcinoma c.1501G>A p.E501K 13
28 COSM4990646 TTLL7 skin,NS,carcinoma,squamous cell carcinoma c.1501-1G>A p.? 13
29 COSM4990647 TTLL7 skin,NS,carcinoma,squamous cell carcinoma c.1001G>A p.G334E 13
30 COSM4990722 TSHR skin,NS,carcinoma,squamous cell carcinoma c.937A>T p.K313* 13
31 COSM4990719 TSHR skin,NS,carcinoma,squamous cell carcinoma c.492G>A p.M164I 13
32 COSM3498383 TSHR skin,NS,carcinoma,squamous cell carcinoma c.1248C>T p.F416F 13
33 COSM4990715 TSHR skin,NS,carcinoma,squamous cell carcinoma c.91T>C p.C31R 13
34 COSM4990717 TSHR skin,NS,carcinoma,squamous cell carcinoma c.171-1G>A p.? 13
35 COSM4990723 TSHR skin,NS,carcinoma,squamous cell carcinoma c.1459G>A p.D487N 13
36 COSM4990721 TSHR skin,NS,carcinoma,squamous cell carcinoma c.693-1G>A p.? 13
37 COSM4990854 TSC2 skin,NS,carcinoma,squamous cell carcinoma c.2707C>T p.P903S 13
38 COSM4990856 TSC2 skin,NS,carcinoma,squamous cell carcinoma c.3330C>T p.A1110A 13
39 COSM4990850 TSC2 skin,NS,carcinoma,squamous cell carcinoma c.2587G>A p.E863K 13
40 COSM4606358 TSC2 skin,NS,carcinoma,squamous cell carcinoma c.1378G>A p.A460T 13
41 COSM4990848 TSC2 skin,NS,carcinoma,squamous cell carcinoma c.1846G>A p.D616N 13
42 COSM4990845 TSC2 skin,NS,carcinoma,squamous cell carcinoma c.1153C>T p.H385Y 13
43 COSM4423739 TSC2 skin,NS,carcinoma,squamous cell carcinoma c.2615C>T p.S872F 13
44 COSM4993227 TSC1 skin,NS,carcinoma,squamous cell carcinoma c.2880G>A p.L960L 13
45 COSM4993229 TSC1 skin,NS,carcinoma,squamous cell carcinoma c.2750C>T p.A917V 13
46 COSM4993232 TSC1 skin,NS,carcinoma,squamous cell carcinoma c.1993A>G p.N665D 13
47 COSM4993226 TSC1 skin,NS,carcinoma,squamous cell carcinoma c.2881G>A p.E961K 13
48 COSM4993231 TSC1 skin,NS,carcinoma,squamous cell carcinoma c.2208+1G>A p.? 13
49 COSM4993228 TSC1 skin,NS,carcinoma,squamous cell carcinoma c.2751C>T p.A917A 13
50 COSM4993230 TSC1 skin,NS,carcinoma,squamous cell carcinoma c.2640G>A p.M880I 13

Expression for Skin Squamous Cell Carcinoma

Search GEO for disease gene expression data for Skin Squamous Cell Carcinoma.

Pathways for Skin Squamous Cell Carcinoma

Pathways related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.06 BIRC5 EIF4E IFNA1 IL10 STAT1 STAT2
2
Show member pathways
12.41 BIRC5 IFNA1 IL10 STAT1 STAT2 TP53
3
Show member pathways
12.37 BIRC5 IL10 STAT1 TP53
4 12.31 IFNA1 IL10 STAT1 STAT2
5
Show member pathways
12.29 EIF4E IFNA1 STAT1 STAT2
6
Show member pathways
12.08 EIF4E IFNA1 STAT1 STAT2
7 12 IFNA1 IL10 STAT1
8 11.95 BIRC5 STAT1 TP53
9
Show member pathways
11.91 IFNA1 IL10 STAT1 STAT2
10
Show member pathways
11.77 IFNA1 IL10 STAT1 STAT2
11 11.74 IFNA1 STAT1 STAT2 TP53
12
Show member pathways
11.73 IL10 STAT1 STAT2
13 11.56 BIRC5 EIF4E TP53
14 11.35 EIF4E STAT1 STAT2
15 11.31 BIRC5 IL10 STAT1 TP53
16
Show member pathways
10.91 STAT1 STAT2
17 10.75 IFNA1 IL10 STAT1 STAT2

GO Terms for Skin Squamous Cell Carcinoma

Biological processes related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.56 EIF4E STAT1 STAT2 TP53
2 defense response to virus GO:0051607 9.5 IFNA1 STAT1 STAT2
3 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.16 IL10 KLF4
4 type I interferon signaling pathway GO:0060337 9.13 IFNA1 STAT1 STAT2
5 regulation of type I interferon-mediated signaling pathway GO:0060338 8.8 IFNA1 STAT1 STAT2

Molecular functions related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 8.92 BIRC5 EIF4E STAT1 TP53

Sources for Skin Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....